Sunil Kumara,
Amritha Manoharana,
Jayalakshmi Ja,
Mohamed A. Abdelgawadbc,
Wael A. Mahdid,
Sultan Alshehrid,
Mohammed M. Ghoneimef,
Leena K. Pappachena,
Subin Mary Zachariaha,
T. P. Aneesh*a and
Bijo Mathew*a
aDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, India. E-mail: bijomathew@aims.amrita.edu; bijovilaventgu@gmail.com; aneeshtp@aims.amrita.edu
bDepartment of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, 72341, Saudi Arabia
cDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt
dDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia
eDepartment of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah, 13713, Saudi Arabia
fPharmacognosy and Medicinal Plants Department, Faculty of Pharmacy, Al-Azhar University, Cairo, 11884, Egypt
First published on 6th April 2023
Correction for ‘Exploiting butyrylcholinesterase inhibitors through a combined 3-D pharmacophore modeling, QSAR, molecular docking, and molecular dynamics investigation’ by Sunil Kumar et al., RSC Adv., 2023, 13, 9513–9529, https://doi.org/10.1039/D3RA00526G.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2023 |